Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by Cytogen Corporation.
Recruitment status was  Recruiting
Study NCT00121095   Information provided by Cytogen Corporation

First Received on July 13, 2005.   Last Updated on December 17, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostatic Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Additional drug interventions recognized in this trial
Docetaxel
Samarium ethylenediaminetetramethylenephosphonate
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Antineoplastic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Cytogen Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services